Lannett Company, Inc develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, suspension, soft gel, and injectable dosages.
Read More…
Industry, Sector and Symbol
Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
WebN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees1,020
Next Earnings Date5/4/2020 (Estimated)
OptionableOptionable
Lannett (NYSE:LCI) Frequently Asked Questions
What is Lannett's stock symbol?
Lannett trades on the New York Stock Exchange (NYSE) under the ticker symbol "LCI."
How were Lannett's earnings last quarter?
Lannett Company, Inc. (NYSE:LCI) issued its earnings results on Wednesday, February, 5th. The company reported $0.27 earnings per share for the quarter, hitting the consensus estimate of $0.27. The business had revenue of $136.11 million for the quarter, compared to analyst estimates of $128.60 million. Lannett's revenue was down 29.7% on a year-over-year basis. During the same period last year, the business posted $0.32 EPS. View Lannett's Earnings History.
When is Lannett's next earnings date?
What guidance has Lannett issued on next quarter's earnings?
Lannett issued an update on its FY 2020
After-Hours earnings guidance on Wednesday, February, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $530-550 million, compared to the consensus revenue estimate of $536.21 million.
What price target have analysts set for LCI?
2 equities research analysts have issued 12-month price objectives for Lannett's stock. Their forecasts range from $14.00 to $14.00. On average, they expect Lannett's stock price to reach $14.00 in the next year. This suggests a possible upside of 53.8% from the stock's current price. View Analyst Price Targets for Lannett.
What is the consensus analysts' recommendation for Lannett?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lannett in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Lannett.
Has Lannett been receiving favorable news coverage?
Media headlines about LCI stock have been trending somewhat positive on Monday, InfoTrie reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Lannett earned a media sentiment score of 1.8 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Lannett.
Who are some of Lannett's key competitors?
Some companies that are related to Lannett include AbbVie (ABBV), Bristol-Myers Squibb (BMY), Allergan (AGN), The Medicines (MDCO), Corcept Therapeutics (CORT), Endo International (ENDP), Assembly Biosciences (ASMB), BioDelivery Sciences International (BDSI), Akorn (AKRX), Ampio Pharmaceuticals (AMPE), Cumberland Pharmaceuticals (CPIX), Acura Pharmaceuticals (ACUR), Melinta Therapeutics (MLNT), Eli Lilly And Co (LLY) and Horizon Therapeutics (HZNP).
What other stocks do shareholders of Lannett own?
Who are Lannett's key executives?
Lannett's management team includes the folowing people:
- Mr. Timothy C. Crew, CEO & Director (Age 58)
- Mr. Martin P. Galvan, VP of Fin. & CFO (Age 67)
- Mr. Samuel H. Israel, Gen. Counsel & Chief Legal Officer (Age 57)
- Mr. John M. Abt, VP & Chief Quality Operations Officer (Age 54)
- Mr. John Kozlowski, Chief of Staff & Strategy Officer (Age 47)
Who are Lannett's major shareholders?
Lannett's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Telemus Capital LLC (19.04%), LSV Asset Management (5.16%), State Street Corp (3.21%), Renaissance Technologies LLC (3.20%), Public Sector Pension Investment Board (1.66%) and Prudential Financial Inc. (1.45%). Company insiders that own Lannett stock include Albert Paonessa III, Jeffrey Farber, Kevin Smith, Patrick G Lepore and Timothy C Crew. View Institutional Ownership Trends for Lannett.
Which institutional investors are selling Lannett stock?
LCI stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Connor Clark & Lunn Investment Management Ltd., Jacobs Levy Equity Management Inc., Telemus Capital LLC, Barclays PLC, IndexIQ Advisors LLC, Globeflex Capital L P and Oxford Asset Management LLP. View Insider Buying and Selling for Lannett.
Which institutional investors are buying Lannett stock?
LCI stock was bought by a variety of institutional investors in the last quarter, including Public Sector Pension Investment Board, AJO LP, X Square Capital LLC, Credit Suisse AG, Massachusetts Financial Services Co. MA, Goldman Sachs Group Inc., AQR Capital Management LLC and Swiss National Bank. Company insiders that have bought Lannett stock in the last two years include Albert Paonessa III, Jeffrey Farber, Patrick G Lepore and Timothy C Crew. View Insider Buying and Selling for Lannett.
How do I buy shares of Lannett?
Shares of LCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Lannett's stock price today?
One share of LCI stock can currently be purchased for approximately $9.10.
MarketBeat Community Rating for Lannett (NYSE LCI)
MarketBeat's community ratings are surveys of what our community members think about Lannett and other stocks. Vote "Outperform" if you believe LCI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LCI will underperform the S&P 500 over the long term. You may vote once every thirty days.
